引用次数
引用: 13,181
H-指数: 61
I10-指数 : 192
出版物: 524
Modelling the impact of referral guideline changes for mild dyskaryosis on colposcopy services in England
A. Brennan , P. Walker , S. Eggington , R. Hadwin
5
2006
A Theory-based Online Health Behaviour Intervention for new University Students: One-month Follow-up Data
T. Epton , A. Petroczi , S.A. Julious , P.S. Meier
The European health psychologist 16 861
2014
The psychometric properties of ADCS - activities of daily living inventory and comparison of different ADL scores
S. Rózsa , A. Brandtmüller , B. Nagy , A. Brennan
1
2009
Comparison of brief interventions in primary care on smoking and alcohol consumption in England
E. Kaner , C. Drummond , E. Beard , A. Brennan
The European health psychologist 17 506
2015
Fuel Poverty: Perspectives from the front line
A. Brennan , S.C.L. Koh , A. Genovese , R. Marchand
Centre for Energy Environment and Sustainability 2012
3
2012
The role of Beta Interferon in the treatment of multiple sclerosis
R.G. Richards , A. Brennan , S.F. Paisley , N.J. Cooper
Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield
1
1996
Prostacyclin and Iloprost in the treatment of primary pulmonary hypertension
R.G. Richards , Stevenson , S.E. Ward , T. Higenbottam
Trent institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield
1997
Considerations concerning the use of health economics in the design and analysis of adaptive clinical trials - a qualitative study
S. Julious , L. Flight , D. Hind , A. Brennan
BioMed Central
2019
POS0734 EXTRAPOLATION OF LONG-TERM OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: REPLICATING A HOPKINS LUPUS COHORT ANALYSIS WITH THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT
Y. St-Pierre , I. N. Bruce , A. Brennan , A. E. Clarke
Annals of the Rheumatic Diseases 80
2021
O4-6.4 The development of models to underpin public health guidance
P. Meier , A. Brennan
Journal of Epidemiology and Community Health 65
2011
PSY1 CONCEPTUALIZING A FRAMEWORK FOR MODELING SYSTEMIC LUPUS ERYTHEMATOSUS
V. Paly , A. Brennan , J. Mukherjee , E. Alemao
Value in Health 22
2019
The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries.
R. Ara , A. Brennan
Obesity Reviews 8 ( 4) 363 -371
17
2007
Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials".
Jon Karnon , A. Brennan , J. Chilcott
European Journal of Health Economics 4 ( 3) 239 -240
1
2003
Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study
A. Brennan , Y. Meng , J. Holmes , D. Hill-McManus
BMJ 349 ( 7977) 5452
44
2014
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort
P. Watson , A. Brennan , H. Birch , H. Fang
Rheumatology 54 ( 4) 623 -632
11
2015
The Sheffield rheumatoid arthritis health economic model
J. Tosh , A. Brennan , A. Wailoo , N. Bansback
Rheumatology 50
22
2011
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis
N. J. Bansback , R. Ara , N. Barkham , A. Brennan
Rheumatology 45 ( 8) 1029 -1038
45
2006
The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
R. Nixon , N. Bansback , A. Brennan
Rheumatology 46 ( 7) 1140 -1147
86
2007
Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
A. Brennan , N. Bansback , R. Nixon , J. Madan
Rheumatology 46 ( 8) 1345 -1354
116
2007
Validation of the SPHR Diabetes Prevention Model.
C. Thomas , P. Watson , H. Squires , J. Chilcott
Value in Health 17 ( 7)
2
2014